Keeping Track: First-In-Class Candidates In COPD, Cancer Join US FDA Review Queue
Executive Summary
Recent applications for approval also include another DMD therapy, another hemophilia B gene therapy, and a new antibiotic.
You may also be interested in...
Geron Sees Blockbuster Opportunity For Imetelstat, Eyeing Broader Market Than Reblozyl’s
The company reported positive results from its study in lower-risk myelodysplastic syndrome, where it forecasts a market potentially exceeding 30,000 in US and major European markets and generating up to $1.2bn in sales.
Pfizer’s Gene Therapy Asset Chases UniQure/CSL’s Hemgenix After Pivotal Hemophilia B Success
Pfizer’s fidanacogene elaparvovec has hit the mark in a Phase III hemophilia B trial just a month after rival UniQure’s Hemgenix won US approval, with Pfizer’s plans for regulatory action raising the stakes for Hemgenix.
Verona Emerges Victorious From Second COPD Trial
After once again showing significant improvements in lung function and a 36% reduction in rate of exacerbations over 24 weeks, Verona is confident that its dual PDE3/4 inhibitor will change the treatment paradigm for COPD.